Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Rationale for short course primaquine in Africa to interrupt malaria transmission.

Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, von Seidlein L, Drakeley C; Primaquine in Africa Discussion Group.

Malar J. 2012 Oct 30;11:360. doi: 10.1186/1475-2875-11-360. Review.

2.

Primaquine for reducing Plasmodium falciparum transmission.

Graves PM, Gelband H, Garner P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008152. doi: 10.1002/14651858.CD008152.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(6):CD008152.

PMID:
22972117
3.

Targeting Plasmodium falciparum transmission with primaquine: same efficacy, improved safety with a lower dose?

Chen IT, Gosling RD.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):681-6. doi: 10.1586/17512433.2014.948421. Epub 2014 Aug 13.

PMID:
25118908
4.

Single Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects.

Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, Kajeechiwa L, Thwin MM, Rakthinthong S, Nosten S, Thinraow S, Nyo SN, Ling CL, Wiladphaingern J, Kiricharoen NL, Moore KA, White NJ, Nosten F.

PLoS One. 2016 Mar 24;11(3):e0151898. doi: 10.1371/journal.pone.0151898. eCollection 2016.

5.

An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia.

Leang R, Khu NH, Mukaka M, Debackere M, Tripura R, Kheang ST, Chy S, Kak N, Buchy P, Tarantola A, Menard D, Roca-Felterer A, Fairhurst RM, Kheng S, Muth S, Ngak S, Dondorp AM, White NJ, Taylor WR.

BMC Med. 2016 Oct 27;14(1):171. Erratum in: BMC Med. 2016 Dec 20;14 (1):213.

6.

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.

White NJ, Qiao LG, Qi G, Luzzatto L.

Malar J. 2012 Dec 14;11:418. doi: 10.1186/1475-2875-11-418. Review.

7.

Spatial distribution of G6PD deficiency variants across malaria-endemic regions.

Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, Sakuntabhai A, Satyagraha AW, Williams TN, Baird JK, Hay SI.

Malar J. 2013 Nov 15;12:418. doi: 10.1186/1475-2875-12-418.

8.

Primaquine: the risks and the benefits.

Ashley EA, Recht J, White NJ.

Malar J. 2014 Nov 3;13:418. doi: 10.1186/1475-2875-13-418. Review.

9.

An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa.

Chen I, Poirot E, Newman M, Kandula D, Shah R, Hwang J, Cohen JM, Gosling R, Rooney L.

Malar J. 2015 May 15;14:204. doi: 10.1186/s12936-015-0714-3.

10.

Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations.

Lawpoolsri S, Klein EY, Singhasivanon P, Yimsamran S, Thanyavanich N, Maneeboonyang W, Hungerford LL, Maguire JH, Smith DL.

Malar J. 2009 Jul 15;8:159. doi: 10.1186/1475-2875-8-159.

11.
12.

The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial.

Okebe J, Bousema T, Affara M, DiTanna G, Eziefula AC, Jawara M, Nwakanma D, Amambua-Ngwa A, Van Geertruyden JP, Drakeley C, D'Alessandro U.

Trials. 2015 Mar 1;16:70. doi: 10.1186/s13063-015-0597-1.

13.

In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.

Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T.

Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1.

14.

Appropriate time for primaquine treatment to reduce Plasmodium falciparum transmission in hypoendemic areas.

Wilairatana P, Krudsood S, Tangpukdee N.

Korean J Parasitol. 2010 Jun;48(2):179-82. doi: 10.3347/kjp.2010.48.2.179. Epub 2010 Jun 17.

15.

Primaquine for prevention of malaria in travelers.

Baird JK, Fryauff DJ, Hoffman SL.

Clin Infect Dis. 2003 Dec 15;37(12):1659-67. Epub 2003 Nov 20.

PMID:
14689349
16.

[A study of artemether combined with primaquine in the treatment of falciparum malaria].

Huang JR, Gao YQ, Elie N.

Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2001;19(5):308-9. Chinese.

PMID:
12572052
17.

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.

Galappaththy GN, Tharyan P, Kirubakaran R.

Cochrane Database Syst Rev. 2013 Oct 26;(10):CD004389. doi: 10.1002/14651858.CD004389.pub3. Review.

PMID:
24163057
18.

Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.

Shah NK, Schapira A, Juliano JJ, Srivastava B, MacDonald PD, Poole C, Anvikar A, Meshnick SR, Valecha N, Mishra N.

Antimicrob Agents Chemother. 2013 Jul;57(7):2948-54. doi: 10.1128/AAC.00139-13. Epub 2013 Apr 15.

19.

Single-Dose Primaquine in a Preclinical Model of Glucose-6-Phosphate Dehydrogenase Deficiency: Implications for Use in Malaria Transmission-Blocking Programs.

Wickham KS, Baresel PC, Marcsisin SR, Sousa J, Vuong CT, Reichard GA, Campo B, Tekwani BL, Walker LA, Rochford R.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5906-13. doi: 10.1128/AAC.00600-16. Print 2016 Oct.

20.

[Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day].

Silva MC, Santos EB, Costal EG, Filho MG, Guerreiro JF, PĆ³voa MM.

Rev Soc Bras Med Trop. 2004 May-Jun;37(3):215-7. Portuguese.

PMID:
15330059

Supplemental Content

Support Center